That letter didn't come from us. It came from a sister organization called the Canadian Cystic Fibrosis Treatment Society.
I'm not going to speak to the leadership of the PMPRB. I think the staff probably work hard there and try to do the best they can.
What I do think is that they didn't have a sound consultation process, one that I would expect would have been more of a to and fro and not a didactic, one-way process. I think patients and people living with disease have a lot to offer. There are many things that I could say about the consultation—and I can submit them later. I think you could have had a more meaningful discussion on the changes.
As Cystic Fibrosis Canada, we've said that we do agree with the lower drug prices and with some of the guideline changes, and then we think that maybe you should wait and see, try some out, see how it goes and learn from the experience.
I think it just becomes very didactic and black and white.
I can't speak to the leadership. I'm sorry that I'm answering you in a bit of a roundabout way.